CTRL + SPACE for auto-complete. Northwind is committed to product and consumer safety. Strides Pharma Science Limited (Strides or the Company) today informed that U S Food and Drug Administration (USFDA or the Agency) on April 1, 2020, has published a statement1and issued letters to all manufacturers of Ranitidine across dosage forms requesting withdrawal of all prescription(Rx) and over-the-counter (OTC) ranitidine drugs from the market immediately. Apotex Corp. has notified its affected direct account Warehousing Chains via mail (FedEx Standard Overnight) by mailing a recall notification letter and is arranging for return of all recalled product.Wholesalers, Distributors and Retailers return the impacted product to place of purchase. He is very knowledgeable about the law and extremely professional.Fill out the form below to receive a free confidential consultation.© Copyrights 2002-2020 YourLawyer.com®. Pharmacies will be asked to immediately stop dispensing Sandoz Ranitidine Hydrochloride Capsules and return remaining stock to Sandoz by contacting Stericycle to request a recall packet. Ranitidine recall 2020: FDA asks for immediate withdrawal of all ranitidine drugs (such as Zantac) Updated Apr 01, 2020; Posted Apr 01, 2020 By The Oregonian/OregonLive No reports of injury or adverse events to date.Ranitidine is used as a short-term treatment for active duodenal ulcers, maintenance therapy for duodenal ulcer patients, treatment of pathological hypersecretory conditions, short-term treatment of active, benign gastric ulcers, maintenance therapy for gastric ulcers, treatment of GERD and treatment of endoscopically diagnosed erosive esophagitis.Product was distributed Nationwide to Wholesalers for use in hospital settings.American Health Packaging has notified its distributors by recall letter, sent November 1st, 2019, to immediately discontinue distribution of the specific lots being recalled and to notify their sub-accounts. Hours of operation are 9:00 am - 5:00 pm, EST Monday through Friday.Consumers who have Ranitidine Tablets, USP which are being recalled should stop using the product or with questions regarding this recall can contact Inmar Pharmaceuticals Services by 800-967-5952 (option 1). Strides recently acquired Vivmed Labs Ltd, which manufactures a generic version of losartan that was recently recalled for being contaminated with impurities that may be harmful to humans. Ranitidine Tablets 150 mg and 300 mg is a prescription oral product approved for multiple indications, including treatment and prevention of ulcers of the stomach and intestines and treatment of gastroesophageal reflux disease.Glenmark is committed to product and consumer safety. Consumers, distributors and retailers that have Ranitidine Oral Solution, USP 150 mg/10 mL, which is being recalled, should stop using and call Precision Dose Inc. at 815-624-8523 to obtain a return packet.Consumers with questions regarding this recall can contact Precision Dose Inc. by phone (815-624-8523), Monday through Friday 8 am to 4:30 pm CST or e-mail us at: Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.GSMS, Inc. received a recall notification from the manufacturer, Novitium, on October 25th, 2019 and initiated a voluntary recall on November 6th, 2019 to the consumer level for 7 lots of Ranitidine HCl 150mg and 12 lots of Ranitidine HCl 300mg Capsules.To date, GSMS, Inc. has not received any reports of adverse events related to the use of the products as part of this recall.Ranitidine Hydrochloride Capsules are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable.GSMS, Inc. has promptly notified its consignees via email and certified mail.